近年來新型口服抗凝藥（NOACs）取得很大的發(fā)展，逐漸取代傳統(tǒng)抗凝藥而成為臨床一線的首選藥物。盡管與傳統(tǒng)抗凝藥物相比，NOACs的出血副作用相當(dāng)或更小，但依然存在著一定的出血風(fēng)險。傳統(tǒng)抗凝藥物的解毒劑對NOACs的解毒效果不佳，為該類藥物的使用帶來很大的風(fēng)險和不便。針對NOACs的特殊解毒劑正在開發(fā)當(dāng)中，前期試驗已取得不錯的結(jié)果。這些解毒劑最具有代表性的藥物包括Portola制藥公司的andexanet alfa、勃林格殷格翰公司的idarucizumab以及Perosphere公司的aripazine，主要針對這3種NOACs解毒劑的研究進展以及存在的問題進行綜述。

In recent years, new oral anticoagulants (NOACs) had made great development, and they gradually replaced the traditional anticoagulants to become the first-line drug of choice for clinic. Compared with conventional anticoagulants, their bleeding side effects were close to or less, but they still had a certain risk of bleeding. Traditional anticoagulant antidotes had poor detoxifying effect of NOACs, which led to a great deal of inconvenience and risk for the use of these drugs. Specific antidotes for NOACs were under development, and preliminary tests had achieved good results. Most representative drugs of these antidotes included andexanet alfa of Portola Pharmaceuticals, idarucizumab of Boehringer Ingelheim, and aripazine of Perosphere. This article reviewed research progress and problems of these three NOACs antidotes.

天津市應(yīng)用基礎(chǔ)與前沿技術(shù)研究計劃青年項目（14JCQNJC13300）